Evidence map›Paper›PMID 40250790›Full record

ArticleCancer letters2025

Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination.

Brittany Rupp, Neha Nagpal, Brooke Thanasiu, Kristen Tuck, Kirk Herman, Dean E Brenner, Justin Colacino, Max Wicha, Sunitha Nagrath

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Lamin A/C as a biomarker for breast cancer.Molecular biology reports · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Brittany RuppDepartment of Chemical Engineering, University of Michigan, USA; BioInterfaces Institute, University of Michigan, USA.
Neha NagpalDepartment of Chemical Engineering, University of Michigan, USA; BioInterfaces Institute, University of Michigan, USA.
Brooke ThanasiuDepartment of Chemical Engineering, University of Michigan, USA.
Kristen TuckRogel Cancer Center, University of Michigan, USA.
Kirk HermanRogel Cancer Center, University of Michigan, USA.
Dean E BrennerRogel Cancer Center, University of Michigan, USA; Department of Pharmacology, University of Michigan, USA; Department of Internal Medicine, University of Michigan, USA.
Justin ColacinoRogel Cancer Center, University of Michigan, USA; Department of Environmental Health Sciences, University of Michigan, USA.
Max WichaRogel Cancer Center, University of Michigan, USA; Department of Internal Medicine, University of Michigan, USA. Electronic address: mwicha@med.umich.edu.
Sunitha NagrathDepartment of Chemical Engineering, University of Michigan, USA; BioInterfaces Institute, University of Michigan, USA; Rogel Cancer Center, University of Michigan, USA. Electronic address: snagrath@umich.edu.

Funding

Targeting breast cancer stem cellsR35CA197585 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WICHA, MAX S. · 2016 to 2022
$6.4M
Diversity SupplementR01ES028802 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin Adam Colacino · 2018 to 2026
$4.8M
Targeting Metabolic Vulnerabilities of Triple Negative Breast Cancer Stem CellsR01CA282098 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MAX S. WICHA · 2024 to 2026
$2.4M
NCI NIH HHS R01 CA282098NCI NIH HHS R35 CA197585NIEHS NIH HHS R01 ES028802
6 · The paper itself

Abstract

While ducal carcinoma in situ (DCIS) is considered to be pre-invasive, some patients will develop metastatic disease after a long disease-free interval. The prevailing dogma posits that invasive local recurrence is the source of subsequent metastasis, and thus the goal of DCIS therapy is the prevention of local recurrence. Recently, this paradigm has been called into question by the observation that some women develop metastatic disease in the absence of local recurrence or even following bilateral mastectomies, suggesting early cancer dissemination in some patients. If the presence of circulating tumor cells (CTCs) can be verified on some patients with pure DCIS, then dissemination may be occurring earlier than previously thought, suggesting that these patients might require additional monitoring or treatment. Here, we present a workflow to isolate and characterize CTCs from DCIS patients. Using a high throughput size based inertial focusing microfluidic device, the Labyrinth, we isolated and identified CTCs in 66.6 % (12/18) of DCIS patients with an average of 1.337 CTCs per five mL. Immunofluorescence staining and single cell qPCR of CTCs reveal mesenchymal characteristics of the cells that may contribute to their ability to migrate and metastasize. Preliminary targeted DNA sequencing revealed single nucleotide variations previously found in DCIS samples. Overall, this data supports the hypothesis that cancer dissemination is occurring in a subset of DCIS patients earlier than previously thought. Additionally, the molecular characterization of CTC in DCIS patients may provide important information on their biological characteristics and associated clinical behavior.

Indexed as

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingNeoplastic Cells, CirculatingAgedBiomarkers, TumorFemaleHumansMiddle AgedBiomarkers, TumorBulk genomicsCirculating tumor cellsDuctal carcinoma in situMicrofluidicsSingle cell transcriptomics

Identifiers

PMID40250790
PMCPMC12068956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.